A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Advances knowledge about the use of tecarfarin in patients with severe kidney impairment, including dialysis Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registration trial Addresses a critical current treatment gap in patients with ESKD PONTE...
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel...
Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE: ABT) validates the need for new anticoagulation...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced that Chairman and CEO Quang X. Pham will...
Management Available for One-to-One Meetings PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced...
Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership...
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage...
James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development...